The S&P 500 soared more than 32% in 2013, and several big pharma companies, namely Bristol-Myers Squibb (BMY -0.34%), AbbVie (ABBV -0.46%), Roche (RHHBY -0.27%), Johnson & Johnson (JNJ 3.09%), and AstraZeneca (AZN 0.32%) also performed extraordinarily well. The following slideshow reveals why these companies beat out their big pharma peers and what drove their strong performances in 2013.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
The pharmaceutical sector had a stellar 2013, but which stocks were the best?
Max Macaluso, Ph.D. owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences, ImmunoGen, and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.